APA (7th ed.) Citation

DS, C., A, N., J, P., L, W., EG, T., JS, H., . . . RG, G. (2023). Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial. Journal of neurotrauma, 40(17-18), 1889. https://doi.org/10.1089/neu.2022.0499

Chicago Style (17th ed.) Citation

DS, Chow, et al. "Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial." Journal of Neurotrauma 40, no. 17-18 (2023): 1889. https://doi.org/10.1089/neu.2022.0499.

MLA (9th ed.) Citation

DS, Chow, et al. "Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial." Journal of Neurotrauma, vol. 40, no. 17-18, 2023, p. 1889, https://doi.org/10.1089/neu.2022.0499.